Rigel Pharmaceuticals, Inc. (RIGL), Thursday announced that it has agreed to acquire the U.S. rights to Gavreto from Blueprint Medicines Corp. for an initial payment of $10 million, followed by an additional $5 million after one year of the closing date.
Blueprint Medicines Corp. found a new U.S. commercialization home for Gavreto (pralsetinib) through an agreement with Rigel Pharmaceuticals Inc. potentially worth $117.5 million, now that Roche Holding AG has relinquished all rights.
CAMBRIDGE, Mass. CAMBRIDGE, Mass. Blueprint Medicines Corp. on Thursday reported a loss of $110.9 million in its fourth quarter. The Cambridge, Massachusetts-based company said it had.
/PRNewswire/ The gastrointestinal stromal tumors therapeutics market is anticipated to grow by USD 1.02 billion, progressing at a CAGR of 6.01% during the.